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Dear Colleague, 
	  
Variant classification methodology, VUS rates, and variant classification data sharing have been prominent 
topics in hereditary cancer testing over the past year as the marketplace for testing has expanded. There 
are a spectrum of opinions and practices among laboratories and providers related to variant classification 
and data sharing, and we are writing to provide you with Myriad’s perspective on public variant databases. 
	  
Myriad believes that variant classification databases used for clinical purposes should be subjected to 
quality assurance oversight. Medical management decisions made on the basis of variant interpretations 
are crucial to the safety and well-being of patients, and we believe the use of unregulated databases poses 
risks to patients. At this time, there are no well-regulated public variant databases that meet the accuracy 
standards necessary to provide good patient care. 
	  
The following short video by one of Myriad’s Laboratory Directors, Dr. Karla Bowles, highlights some of the 
concerns regarding use of public databases for clinical care: 
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Please watch the video and consider the following: 
	  
Myriad shared data with the Breast Information Core (BIC) database until 2007. Myriad decided to 
stop contributing to the BIC based upon instances of reclassified variants not being updated in the 
database and the knowledge that the lack of timely updates was having a negative impact on patient 
care. 
	  
Current public variant databases were designed for research purposes and are not maintained or 
regulated in a way that provides appropriate patient care. They lack proper quality control to ensure 
that the information is entered accurately and that any changes in classification are updated in a 
timely fashion. There is currently no mechanism to alert providers or patients when a reclassification 
occurs so patients may be over or undermanaged unnecessarily. 
	  
Both the NIH and ACMG have statements regarding the inaccuracies and potential harms of public 
databases. 
	  
Myriad recently evaluated and compared classifications of over 2,000 variants in BRCA1 and BRCA2 
among 5 public databases with the Myriad database. Results show a wide disparity in classification 
among and within databases that can lead to patient mismanagement if public databases are relied 
upon for clinical care. Myriad will be sharing this information in an upcoming publication. 
	  
The ultimate consequence of inaccurate and outdated information in public variant databases is 
negative outcomes for patient care and safety related to false negative, false positive, and 
misclassified VUS results. 
	  
Myriad is dedicated to furthering genetic science and has engaged in hundreds of scientific collaborations 
with many top institutions to help advance medical and scientific knowledge. For more information please 
visit: https://www.myriad.com/responsibility/research-collaborations/. 
	  
Myriad recently announced its participation in a research collaboration with leading cancer institutes to 
advance the understanding of the risks associated with multiple cancer genes that are being analyzed 
through next generation sequencing technology. Myriad will be contributing thousands of mutations to the 
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Prospective Registry of Multiplex Testing (PROMPT) collaboration in addition to facilitating additional 
studies to characterize the significance of mutations and providing scientific expertise. For more 
information on Myriad’s participation in the PROMPT study please view the press release here. 
	  
For additional information on Myriad and resources for your practice, please visit: www.MyriadPro.com. 
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